Business Context and Reporting Period
Company: Dermata Therapeutics, Inc. (DRMA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Dermata is a science-driven dermatologic company that executed a strategic pivot in September 2025 from developing prescription products to launching direct-to-consumer (DTC) skincare solutions under the "Tome" brand. The company anticipates the commercial launch of its first product, the "Foundational Treatment," on August 25, 2026. As of the filing date, the company has not generated any revenue.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,814,769) | $(4,004,680) |
| Net Loss Per Share (Basic & Diluted) | $(1.22) | $(5.18) |
| Cash and Cash Equivalents (End of Period) | $4,412,764 | $6,480,930 |
| Net Cash Used in Operating Activities | $(4,901,246) | $(4,624,547) |
| Net Cash Provided by Financing Activities | $1,902,699 | $7,943,907 |
| Total Assets | $5,320,799 | $7,863,826 (Dec 31, 2025) |
| Total Liabilities | $1,833,079 | $1,640,446 (Dec 31, 2025) |
| Accumulated Deficit | $(78,048,665) | $(69,680,019) (June 30, 2025) |
Operating Expenses (Six Months Ended June 30, 2026):
- Research and Development: $596,287
- Selling, General and Administrative (SG&A): $4,343,662
Material Changes vs. Prior Period
- Expense Shift: SG&A expenses increased by $2.1 million (96%) compared to the prior year period, driven by pre-launch commercialization activities, marketing spend, and increased legal fees related to ongoing litigation. Conversely, R&D expenses decreased by $1.3 million (69%) as the company shifted focus from clinical trials to product launch.
- Cash Position: Cash and cash equivalents decreased by approximately $3.1 million during the six-month period, primarily due to operating losses and increased inventory and prepaid asset build-up for the upcoming product launch.
- Financing Activity: The company raised approximately $2.0 million in net proceeds from At-The-Market (ATM) sales in Q1 2026. This contrasts with the prior year period, which saw significant capital raises via PIPE financings totaling nearly $8.0 million in net proceeds.
- Inventory: The company recorded $149,734 in inventory as of June 30, 2026, compared to zero in the prior year, reflecting procurement of raw materials for the Tome skincare line.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the 12 months following the filing date. Cash resources are expected to fund operations only into the fourth quarter of 2026. Additional capital will be required to sustain operations and support the product launch.
- Product Launch: The company expects to launch its first DTC product, "Foundational Treatment," on August 25, 2026. Pricing is set at $178.00 USD per kit (approx. $45 per treatment).
- Legal Proceedings: The company is involved in significant litigation with Villani, Inc. regarding the license for Spongilla-based products. Villani alleges breach of contract and false advertising. While a preliminary injunction was denied in August 2026, the lawsuit and a parallel arbitration seeking money damages remain pending. The company cannot estimate potential losses.
- Supply Chain Risk: The company relies on a single Russian supplier (Reka-Farm) for its key raw material, Spongilla. Ongoing sanctions and export controls related to the war in Ukraine pose a risk to future supply, though the company currently holds sufficient inventory for the initial launch.
- Listing Risk: The company's market value of listed securities is below the $5 million threshold required by Nasdaq. Recent rule changes could lead to immediate suspension and delisting if the market value remains below this threshold for 30 consecutive business days once the rule is fully effective.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "fourth quarter 2026" cash runway estimate given the high burn rate and upcoming marketing spend.
- Legal Exposure: Monitor the status of the Villani, Inc. lawsuit and arbitration, specifically regarding potential damages or permanent injunctions that could halt product sales.
- Supply Chain Continuity: Confirm the company's ability to secure future shipments of Spongilla raw materials from Russia amidst evolving geopolitical sanctions.
- Nasdaq Compliance: Track the company's market capitalization and share price to assess the risk of delisting under the new Market Value of Listed Securities (MVLS) requirements.
- Capital Raising: Assess the feasibility and terms of potential future equity or debt financing required to bridge the gap beyond Q4 2026.